Protalix BioTherapeutics, Inc. (DE) Common Stock (PLX)
2.4350
+0.0550 (2.31%)
Protalix Biotherapeutics is a biotechnology company focused on developing and commercializing innovative therapies for the treatment of rare and chronic diseases
Utilizing its proprietary oral protein manufacturing platform, the company works to produce biopharmaceuticals that can provide effective treatment alternatives for patients. Protalix is particularly dedicated to addressing unmet medical needs and improving the quality of life for individuals suffering from conditions such as enzyme deficiencies, leveraging its expertise in biochemistry and molecular biology to advance its therapeutic pipeline.
Frequently Asked Questions
Is Protalix BioTherapeutics, Inc. (DE) Common Stock publicly traded?
Yes, Protalix BioTherapeutics, Inc. (DE) Common Stock is publicly traded.
What exchange does Protalix BioTherapeutics, Inc. (DE) Common Stock trade on?
Protalix BioTherapeutics, Inc. (DE) Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Protalix BioTherapeutics, Inc. (DE) Common Stock?
The ticker symbol for Protalix BioTherapeutics, Inc. (DE) Common Stock is PLX on the New York Stock Exchange
What is the current price of Protalix BioTherapeutics, Inc. (DE) Common Stock?
The current price of Protalix BioTherapeutics, Inc. (DE) Common Stock is 2.435
When was Protalix BioTherapeutics, Inc. (DE) Common Stock last traded?
The last trade of Protalix BioTherapeutics, Inc. (DE) Common Stock was at 12:50 pm EST on January 31st, 2025
What is the market capitalization of Protalix BioTherapeutics, Inc. (DE) Common Stock?
The market capitalization of Protalix BioTherapeutics, Inc. (DE) Common Stock is 179.30M
How many shares of Protalix BioTherapeutics, Inc. (DE) Common Stock are outstanding?
Protalix BioTherapeutics, Inc. (DE) Common Stock has 73.63M shares outstanding.